Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Patient and occupational safety

CN30 - Three stage capacity: Consent process for systemic anti-cancer therapy

Date

11 Sep 2022

Session

Patient and occupational safety

Topics

Patient Education and Advocacy;  Cytotoxic Therapy;  Immunotherapy;  Radiation Oncology

Tumour Site

Presenters

Fiona Barrett

Citation

Annals of Oncology (2022) 33 (suppl_7): S818-S819. 10.1016/annonc/annonc1044

Authors

F.E. Barrett1, O.M. Fitzpatrick1, T. Doyle1, W.M. Grogan1, D.J. McMahon1, N. Cooley1, A.G. Murphy1, M. Conroy1, L. Judge1, J. Naidoo2, R.A. Mclaughlin1, C. Matassa1, P.G. Morris1, B.T. Hennessy2, M. Breathnach3, K. Egan4, D. O'Doherty1, O.S. Breathnach1

Author affiliations

  • 1 Medical Oncology, Beaumont RCSI Cancer Centre, D09 FT51 - Dublin/IE
  • 2 Medical Oncology / Rcsi, Beaumont RCSI Cancer Centre, D09 FT51 - Dublin/IE
  • 3 3rd Law, National University of Ireland - University College Dublin, D04 V1W8 - Dublin/IE
  • 4 Cancer Clinical Trials Uint, Beaumont RCSI Cancer Centre, D09 FT51 - Dublin/IE
More

Resources

Abstract CN30

Background

The decision to undergo systemic anti-cancer therapy by patients with cancer is a complicated process. The decision is based around many variables. Consent requires that a person has the capacity to consent. Medical decision making capacity must include the following attributes: understanding the nature of their cancer, appreciation of the range of potential options, weighing up the pros and cons of each option and the ability to reach a decision that is communicated. We sought to strengthen our approach to the consent process through a “3-stage capacity-consent process”, performed over 3 occasions prior to delivery of the relevant therapy.

Methods

All patients starting a new plan of intravenous therapy were offered participation in the “3-Stage Capacity-Consent Process”. Patients were initially assessed by a senior medical oncologist who discussed the person's cancer, the treatment options & side-effects, predicted outcomes with each approach, and planned an appropriate treatment. On the same day patients were further educated on the aspects of the proposed treatment by a liaison clinical nurse specialist. Within 10 days they were reviewed by a different oncology doctor and a different clinical nurse specialist who answered any questions posed, gave further education and proceeded to the signing of a consent to medical treatment form. On the day of the first dose of treatment patients were once again given the opportunity to ask questions of a doctor and oncology nurse prior to treatment administration.

Results

Between 4/21 and 9/21 126 patients were included in the pilot study. Female patients represented 37% of the cohort. The median age of patients was 65 yrs (range: 20-89). 32% of patients were consented for immunotherapy-related regimens. 13% were having concurrent chemotherapy-radiation therapy. The remaining 55% had cytotoxic chemotherapy. All patients offered the 3-stage process engaged and participated fully in the program.

Conclusions

A 3 stage capacity - consent process is possible, and allows several phases of “information processing time” by patients and their families, ensuring adequate time to show a patient's capacity to be able to consent to their proposed treatment. This pilot approach is being expanded to all patients attending our Cancer Centre.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Beaumont Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.